Which has stronger earnings and valuation, GANX or RKTO?

Gain Therapeutics is trading at a lower price-to-earnings ratio than Rocket One Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gain Therapeutics N/A N/A -$20.16M -$0.58 N/A Rocket One Inc. Common Stock N/A N/A -$12.47M -$0.80 N/A

Is GANX or RKTO more profitable?

Rocket One Inc. Common Stock's return on equity of -165.25% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -201.44% -136.24% Rocket One Inc. Common Stock N/A -165.25% -143.61%

Which has higher valuation & earnings, RKTO or CYPH?

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Rocket One Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rocket One Inc. Common Stock N/A N/A -$12.47M -$0.80 N/A Cypherpunk Technologies N/A N/A $4.82M -$0.02 N/A

Is RKTO or CYPH more profitable?

Cypherpunk Technologies' return on equity of -48.33% beat Rocket One Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Rocket One Inc. Common Stock N/A -165.25% -143.61% Cypherpunk Technologies N/A -48.33% -42.21%

Do analysts rate XBIT or RKTO?

Rocket One Inc. Common Stock has a consensus target price of $5.00, indicating a potential upside of 449.45%. Given Rocket One Inc. Common Stock's stronger consensus rating and higher probable upside, analysts clearly believe Rocket One Inc. Common Stock is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Rocket One Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, XBIT or RKTO?

XBiotech is trading at a lower price-to-earnings ratio than Rocket One Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XBiotech N/A N/A -$45.54M -$1.32 N/A Rocket One Inc. Common Stock N/A N/A -$12.47M -$0.80 N/A

Is XBIT or RKTO more profitable?

XBiotech's return on equity of -26.10% beat Rocket One Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets XBiotech N/A -26.10% -25.06% Rocket One Inc. Common Stock N/A -165.25% -143.61%

Does the media refer more to XBIT or RKTO?

In the previous week, Rocket One Inc. Common Stock had 1 more articles in the media than XBiotech. MarketBeat recorded 2 mentions for Rocket One Inc. Common Stock and 1 mentions for XBiotech. Rocket One Inc. Common Stock's average media sentiment score of 0.30 beat XBiotech's score of 0.00 indicating that Rocket One Inc. Common Stock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XBiotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rocket One Inc. Common Stock 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, PLRX or RKTO?

Rocket One Inc. Common Stock is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pliant Therapeutics N/A N/A -$149.34M -$1.84 N/A Rocket One Inc. Common Stock N/A N/A -$12.47M -$0.80 N/A

Is PLRX or RKTO more profitable?

Pliant Therapeutics' return on equity of -58.11% beat Rocket One Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Pliant Therapeutics N/A -58.11% -44.37% Rocket One Inc. Common Stock N/A -165.25% -143.61%

Rocket One Inc. Common Stock (RKTO) Competitors

$0.91 +0.11 (+13.41%)

As of 04:00 PM Eastern

Compare

RKTO vs. GANX, CLNN, CYPH, XBIT, and PLRX

Should you buy Rocket One Inc. Common Stock stock or one of its competitors? MarketBeat compares Rocket One Inc. Common Stock with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rocket One Inc. Common Stock include Gain Therapeutics (GANX), Clene (CLNN), Cypherpunk Technologies (CYPH), XBiotech (XBIT), and Pliant Therapeutics (PLRX). These companies are all part of the "pharmaceutical products" industry.

How does Rocket One Inc. Common Stock compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Rocket One Inc. Common Stock (NASDAQ:RKTO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

Gain Therapeutics has a beta of 0.15, suggesting that its stock price is 85% less volatile than the broader market. Comparatively, Rocket One Inc. Common Stock has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

In the previous week, Rocket One Inc. Common Stock had 2 more articles in the media than Gain Therapeutics. MarketBeat recorded 2 mentions for Rocket One Inc. Common Stock and 0 mentions for Gain Therapeutics. Rocket One Inc. Common Stock's average media sentiment score of 0.30 beat Gain Therapeutics' score of 0.00 indicating that Rocket One Inc. Common Stock is being referred to more favorably in the news media.

Company	Overall Sentiment
Gain Therapeutics	Neutral
Rocket One Inc. Common Stock	Neutral

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 7.1% of Rocket One Inc. Common Stock shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by insiders. Comparatively, 6.9% of Rocket One Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Gain Therapeutics presently has a consensus target price of $7.50, suggesting a potential upside of 312.09%. Rocket One Inc. Common Stock has a consensus target price of $5.00, suggesting a potential upside of 449.45%. Given Rocket One Inc. Common Stock's higher possible upside, analysts plainly believe Rocket One Inc. Common Stock is more favorable than Gain Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Rocket One Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Rocket One Inc. Common Stock's return on equity of -165.25% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-201.44%	-136.24%
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%

Gain Therapeutics is trading at a lower price-to-earnings ratio than Rocket One Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	N/A	N/A	-$20.16M	-$0.58	N/A
Rocket One Inc. Common Stock	N/A	N/A	-$12.47M	-$0.80	N/A

Summary

Rocket One Inc. Common Stock beats Gain Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Rocket One Inc. Common Stock compare to Clene?

Rocket One Inc. Common Stock (NASDAQ:RKTO) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Rocket One Inc. Common Stock presently has a consensus price target of $5.00, indicating a potential upside of 449.45%. Clene has a consensus price target of $33.25, indicating a potential upside of 432.00%. Given Rocket One Inc. Common Stock's higher possible upside, equities analysts plainly believe Rocket One Inc. Common Stock is more favorable than Clene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket One Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Rocket One Inc. Common Stock has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Rocket One Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%
Clene	-25,009.70%	N/A	-137.98%

7.1% of Rocket One Inc. Common Stock shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 6.9% of Rocket One Inc. Common Stock shares are held by insiders. Comparatively, 28.3% of Clene shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Rocket One Inc. Common Stock had 2 more articles in the media than Clene. MarketBeat recorded 2 mentions for Rocket One Inc. Common Stock and 0 mentions for Clene. Rocket One Inc. Common Stock's average media sentiment score of 0.30 beat Clene's score of 0.00 indicating that Rocket One Inc. Common Stock is being referred to more favorably in the media.

Company	Overall Sentiment
Rocket One Inc. Common Stock	Neutral
Clene	Neutral

Rocket One Inc. Common Stock has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Clene has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

Rocket One Inc. Common Stock has higher earnings, but lower revenue than Clene. Clene is trading at a lower price-to-earnings ratio than Rocket One Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket One Inc. Common Stock	N/A	N/A	-$12.47M	-$0.80	N/A
Clene	$134K	595.99	-$26.17M	-$3.20	N/A

Summary

Rocket One Inc. Common Stock beats Clene on 8 of the 15 factors compared between the two stocks.

How does Rocket One Inc. Common Stock compare to Cypherpunk Technologies?

Rocket One Inc. Common Stock (NASDAQ:RKTO) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

In the previous week, Rocket One Inc. Common Stock had 1 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 2 mentions for Rocket One Inc. Common Stock and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 0.50 beat Rocket One Inc. Common Stock's score of 0.30 indicating that Cypherpunk Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket One Inc. Common Stock	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cypherpunk Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Rocket One Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket One Inc. Common Stock	N/A	N/A	-$12.47M	-$0.80	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A

Rocket One Inc. Common Stock has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market.

7.1% of Rocket One Inc. Common Stock shares are held by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are held by institutional investors. 6.9% of Rocket One Inc. Common Stock shares are held by company insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cypherpunk Technologies' return on equity of -48.33% beat Rocket One Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%
Cypherpunk Technologies	N/A	-48.33%	-42.21%

Rocket One Inc. Common Stock presently has a consensus target price of $5.00, indicating a potential upside of 449.45%. Cypherpunk Technologies has a consensus target price of $0.90, indicating a potential upside of 28.57%. Given Rocket One Inc. Common Stock's higher possible upside, equities analysts clearly believe Rocket One Inc. Common Stock is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket One Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Cypherpunk Technologies beats Rocket One Inc. Common Stock on 8 of the 14 factors compared between the two stocks.

How does Rocket One Inc. Common Stock compare to XBiotech?

XBiotech (NASDAQ:XBIT) and Rocket One Inc. Common Stock (NASDAQ:RKTO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

XBiotech's return on equity of -26.10% beat Rocket One Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-26.10%	-25.06%
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%

Rocket One Inc. Common Stock has a consensus target price of $5.00, indicating a potential upside of 449.45%. Given Rocket One Inc. Common Stock's stronger consensus rating and higher probable upside, analysts clearly believe Rocket One Inc. Common Stock is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Rocket One Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Rocket One Inc. Common Stock had 1 more articles in the media than XBiotech. MarketBeat recorded 2 mentions for Rocket One Inc. Common Stock and 1 mentions for XBiotech. Rocket One Inc. Common Stock's average media sentiment score of 0.30 beat XBiotech's score of 0.00 indicating that Rocket One Inc. Common Stock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XBiotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rocket One Inc. Common Stock	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

XBiotech is trading at a lower price-to-earnings ratio than Rocket One Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A
Rocket One Inc. Common Stock	N/A	N/A	-$12.47M	-$0.80	N/A

XBiotech has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Rocket One Inc. Common Stock has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 7.1% of Rocket One Inc. Common Stock shares are owned by institutional investors. 30.8% of XBiotech shares are owned by insiders. Comparatively, 6.9% of Rocket One Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Rocket One Inc. Common Stock beats XBiotech on 9 of the 13 factors compared between the two stocks.

How does Rocket One Inc. Common Stock compare to Pliant Therapeutics?

Pliant Therapeutics (NASDAQ:PLRX) and Rocket One Inc. Common Stock (NASDAQ:RKTO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Pliant Therapeutics' return on equity of -58.11% beat Rocket One Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-58.11%	-44.37%
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%

In the previous week, Rocket One Inc. Common Stock had 2 more articles in the media than Pliant Therapeutics. MarketBeat recorded 2 mentions for Rocket One Inc. Common Stock and 0 mentions for Pliant Therapeutics. Rocket One Inc. Common Stock's average media sentiment score of 0.30 beat Pliant Therapeutics' score of 0.00 indicating that Rocket One Inc. Common Stock is being referred to more favorably in the news media.

Company	Overall Sentiment
Pliant Therapeutics	Neutral
Rocket One Inc. Common Stock	Neutral

Pliant Therapeutics has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, Rocket One Inc. Common Stock has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Rocket One Inc. Common Stock is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	N/A	N/A	-$149.34M	-$1.84	N/A
Rocket One Inc. Common Stock	N/A	N/A	-$12.47M	-$0.80	N/A

97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 7.1% of Rocket One Inc. Common Stock shares are owned by institutional investors. 8.0% of Pliant Therapeutics shares are owned by insiders. Comparatively, 6.9% of Rocket One Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Pliant Therapeutics presently has a consensus target price of $3.00, suggesting a potential upside of 165.49%. Rocket One Inc. Common Stock has a consensus target price of $5.00, suggesting a potential upside of 449.45%. Given Rocket One Inc. Common Stock's stronger consensus rating and higher possible upside, analysts plainly believe Rocket One Inc. Common Stock is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Rocket One Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Pliant Therapeutics and Rocket One Inc. Common Stock tied by winning 6 of the 12 factors compared between the two stocks.

Get Rocket One Inc. Common Stock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RKTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RKTO vs. The Competition

Export

Metric	Rocket One Inc. Common Stock	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$20.31M	$3.78B	$6.90B	$12.60B
Dividend Yield	N/A	2.15%	2.67%	7.38%
P/E Ratio	-1.14	21.89	27.42	24.62
Price / Sales	N/A	186.56	495.24	79.46
Price / Cash	N/A	148.60	49.31	57.01
Price / Book	2.28	8.62	11.02	6.45
Net Income	-$12.47M	$23.87M	$3.57B	$331.61M
7 Day Performance	2.48%	0.94%	0.41%	-0.42%
1 Month Performance	-28.91%	12.09%	5.76%	2.09%
1 Year Performance	-36.36%	57.06%	31.25%	22.24%

Rocket One Inc. Common Stock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RKTO Rocket One Inc. Common Stock	1.9828 of 5 stars	$0.91 +13.4%	$5.00 +449.5%	-38.3%	$20.31M	N/A	N/A	4	News Coverage Gap Up High Trading Volume
GANX Gain Therapeutics	2.0218 of 5 stars	$1.83 +0.8%	$7.50 +311.0%	+6.5%	$77.84M	$50K	N/A	20
CLNN Clene	2.7467 of 5 stars	$6.08 +1.2%	$33.25 +446.9%	+60.0%	$77.70M	$200K	N/A	100
CYPH Cypherpunk Technologies	2.3866 of 5 stars	$0.72 +7.3%	$0.90 +24.2%	+104.8%	$77.14M	N/A	N/A	40	Gap Up
XBIT XBiotech	0.2697 of 5 stars	$2.38 -1.2%	N/A	-22.1%	$72.84M	N/A	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RKTO) was last updated on 7/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rocket One Inc. Common Stock (RKTO) Competitors

RKTO vs. GANX, CLNN, CYPH, XBIT, and PLRX

How does Rocket One Inc. Common Stock compare to Gain Therapeutics?

Summary

How does Rocket One Inc. Common Stock compare to Clene?

Summary

How does Rocket One Inc. Common Stock compare to Cypherpunk Technologies?

Summary

How does Rocket One Inc. Common Stock compare to XBiotech?

Summary

How does Rocket One Inc. Common Stock compare to Pliant Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RKTO vs. The Competition

Rocket One Inc. Common Stock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rocket One Inc. Common Stock (RKTO) Competitors

RKTO vs. GANX, CLNN, CYPH, XBIT, and PLRX

How does Rocket One Inc. Common Stock compare to Gain Therapeutics?

Which has more risk and volatility, GANX or RKTO?

Does the media refer more to GANX or RKTO?

Do institutionals and insiders hold more shares of GANX or RKTO?

Do analysts rate GANX or RKTO?

Is GANX or RKTO more profitable?

Which has stronger earnings and valuation, GANX or RKTO?

Summary

How does Rocket One Inc. Common Stock compare to Clene?

Do analysts recommend RKTO or CLNN?

Is RKTO or CLNN more profitable?

Do insiders and institutionals believe in RKTO or CLNN?

Does the media favor RKTO or CLNN?

Which has more risk and volatility, RKTO or CLNN?

Which has better earnings and valuation, RKTO or CLNN?

Summary

How does Rocket One Inc. Common Stock compare to Cypherpunk Technologies?

Does the media prefer RKTO or CYPH?

Which has higher valuation & earnings, RKTO or CYPH?

Which has more volatility and risk, RKTO or CYPH?

Do institutionals & insiders hold more shares of RKTO or CYPH?

Is RKTO or CYPH more profitable?

Do analysts recommend RKTO or CYPH?

Summary

How does Rocket One Inc. Common Stock compare to XBiotech?

Is XBIT or RKTO more profitable?

Do analysts rate XBIT or RKTO?

Does the media refer more to XBIT or RKTO?

Which has higher valuation & earnings, XBIT or RKTO?

Which has more volatility and risk, XBIT or RKTO?

Do insiders and institutionals believe in XBIT or RKTO?

Summary

How does Rocket One Inc. Common Stock compare to Pliant Therapeutics?

Is PLRX or RKTO more profitable?

Does the media prefer PLRX or RKTO?

Which has more volatility and risk, PLRX or RKTO?

Which has stronger valuation and earnings, PLRX or RKTO?

Do insiders & institutionals hold more shares of PLRX or RKTO?

Do analysts prefer PLRX or RKTO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RKTO vs. The Competition

Rocket One Inc. Common Stock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools